Incidence and survival of rare cancers in the US and Europe.

Laura Botta, Gemma Gatta, Annalisa Trama, Alice Bernasconi, Elad Sharon, Riccardo Capocaccia, Angela B. Mariotto

Research output: Contribution to journalArticlepeer-review

Abstract

Geographical variability of cancer burden was almost exclusively estimated for common cancers. Since rare cancers (RC) have become an area of priority for basic and clinical research and public health organizations, this paper provides, using a common methodology, a detailed comparison of incidence and survival for RC in the US and Europe. We estimated incidence and net survival of 199 malignant RC from data of 2 580 000 patients collected by 18 US-SEER and 94 European registries, diagnosed within the most recent common period 2000-2007. RC were defined according to the criterion of crude annual incidence rates textless6/100 000. In total, 196 RC were classified as rare in both populations. Of these, 43 had incidence rates significantly different by at least 0.2 per 100 000:34 higher in the US and 9 higher in Europe. Five-year net survival for all RC combined significantly differed: 5482 RC was significantly higher in the US vs 6 higher in Europe. Differences were not concentrated in a particular cancer family, and were mostly relevant for cases diagnosed textgreater65+ years of age. Use of standardized methods evidenced that incidence and survival rate of majority of RC were higher in the United States compared to Europe. Possible reasons for such differences, requiring further studies, include distribution of risk factors, ability to diagnose RC, different registration practices, and use of updated International Classification of Diseases for Oncology.
Original languageEnglish
Pages (from-to)5632-5642
Number of pages11
JournalCancer Med.
Volume9
Issue number15
DOIs
Publication statusPublished - Aug 1 2020

Keywords

  • *Europe
  • *5 years net survival
  • *differences
  • *incidence
  • *rare cancers
  • *USA

Fingerprint Dive into the research topics of 'Incidence and survival of rare cancers in the US and Europe.'. Together they form a unique fingerprint.

Cite this